Generalizable and reliable AI for early detection of melanoma

The Sloan-Kettering Institute for Cancer Research was awarded a $1,197,158 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the early detection of melanoma using generalized and reliable AI techniques. The grant term runs from June 15, 2024 to June 14, 2027. The research involves collaboration between investigators at Sloan-Kettering, Northeastern University, Melanoma Institute Australia, and Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer. The research aims to develop innovative AI-based methods for early detection of melanoma that can be reliably applied across diverse patient populations. Key project activities include clinical data collection, machine learning model development, and validation studies. The sub-award to Melanoma Institute Australia supports their participation in the clinical research and data analysis components of the project.